Bupropion as Methamphetamine Addiction Treatment Holds Promise

	Tweet

A new study led by researchers at UCLA’s Semel Institute suggests the antidepressant Bupropion may help treat methamphetamine addiction. No medications presently are approved for treating methamphetamine addicts.

Appearing Nov. 23, 2005, as an advance online publication of the peer-reviewed journal Neuropsychopharmacology, the study finds bupropion blunts the methamphetamine “high” and reduces cravings prompted by visual cues such as ambient drug use.

The research team hypothesizes that Bupropion reduces the effects of methamphetamine by preventing the drug from entering brain cells, where methamphetamine can produce release of neurotransmitters that cause feelings of euphoria.

The study is the first to examine the effectiveness of bupropion for treating methamphetamine addiction in humans. A multi-site Phase II clinical trial led by UCLA researchers is in progress.

“Finding new, effective ways to treat methamphetamine addiction is a key component of bringing the ongoing epidemic of abuse under control,” said Dr. Thomas F. Newton, the study’s principal investigator and professor at the Semel Institute for Neuroscience and Human Behavior.

“Burproprion’s novel effect on the brain is what makes this line of research so promising,” added Newton, who also is a professor of psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA. These findings may point the way toward medications with even greater potential to be helpful.”

Twenty of 26 participants enrolled in the project completed the study. Participants were active methamphetamine users between ages 18 and 45. Researchers randomly assigned each participant to receive treatment either with a placebo—an inactive ingredient such as a sugar pill—or bupropion.

Each participant received a series of three intravenous doses of methamphetamine as the study began and a second, identical series of doses six days after treatment with placebo or Bupropion began.

Using a variety of subjective rating scales and questionnaires, participants reported on the subjective effects of the methamphetamine use at baseline and again after treatment with placebo or bupropion. Subjects who took the medication reported a lesser high after treatment.

Each set of research subjects reported similarly on cravings, both at baseline and after treatment, after watching a video with actors portraying methamphetamine use. Subjects who took Buproprion reported less intense craving.

The study was funded by the National Institute on Drug Abuse.

RELATED STORIES:
Pfizer says net profit leaps 50 percent   FDA says AstraZeneca Crestor ad is misleading   Celebrex not as bad for heart as Vioxx   Next-generation drug development: risky and costly, but worth it   Statins may cut stroke disability, deaths   FDA delays nonprescription morning-after pill rule   Vanderbilt Medical Experts Propose FDA Drug Approval Changes   Glaxo hopes for pandemic flu vaccine by yr-end   Caraco reports U.S. FDA approval to market generic glucotrol   Onyx Shares Fall on Cancer Drug Filing   Don’t compromise safety, says drug import report   Existing Drugs Considered to Treat Addiction

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]